Report Publication Announcement • Mar 11, 2022
Report Publication Announcement
Open in ViewerOpens in native device viewer
Press Release
Paris, France, March 11, 2022, 7:30 am CET – GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today announced its financial calendar for 2022.
| Information | Date* |
|---|---|
| 2021 4Q Cash Position | January 18, 2022 |
| 2021 Full-Year Financial Update and Statements | April 8, 2022 (1) |
| 2022 1Q Cash Position | April 21, 2022 |
| Annual General Meeting | May 25, 2022 |
| 2022 First-Half Financial Update and Statements | July 28, 2022 |
| 2022 3Q Cash Position | October 27, 2022 |
| 2022 4Q Cash Position | January 26, 2023 |
(1) Initially planned on March 10, 2022
* This financial calendar is provided for information only and may be subject to changes. The Company's updated financial calendar is available on its corporate website.
Chief Financial Officer Thomas Gidoin [email protected] +33 (0)1 76 21 72 20
Investor Relations Guillaume van Renterghem [email protected] +41 (0)76 735 01 31
Media Relations Marion Janic [email protected] +1-646-537-5649
Retail Investors James Palmer [email protected] +33 (0)7 60 92 77 74
GenSight Biologics S.A. is a clinical-stage biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders. GenSight Biologics' pipeline leverages two core technology platforms, the Mitochondrial Targeting Sequence (MTS) and optogenetics, to help preserve or restore vision in patients suffering from blinding retinal diseases. Using its gene therapy-based approach, GenSight Biologics' product candidates are designed to be administered in a single treatment to each eye by intravitreal injection to offer patients a sustainable functional visual recovery. Developed as a treatment for Leber Hereditary Optic Neuropathy (LHON), GenSight Biologics' lead product candidate, LUMEVOQ® (GS010; lenadogene nolparvovec), is currently in the review phase of its registration process in Europe, and in Phase III to move forward to a BLA filing in the U.S.
Building tools?
Free accounts include 100 API calls/year for testing.
Have a question? We'll get back to you promptly.